Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
Abstract Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-08-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-021-00319-3 |
| _version_ | 1818645008501178368 |
|---|---|
| author | Xin Qing Wenjing Xu Jingjing Zong Xuanlong Du Hao Peng Yewei Zhang |
| author_facet | Xin Qing Wenjing Xu Jingjing Zong Xuanlong Du Hao Peng Yewei Zhang |
| author_sort | Xin Qing |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced HCC remains to be resolved. Fortunately, the past few years have shown the emergence of successful systemic therapies to treat HCC. At the molecular level, HCC is a heterogeneous disease, and current research on the molecular characteristics of HCC has revealed numerous therapeutic targets. Targeted agents based on signalling molecules have been successfully supported in clinical trials, and molecular targeted therapy has already become a milestone for disease management in patients with HCC. Immunotherapy, a viable approach for the treatment of HCC, recognizes the antigens expressed by the tumour and treats the tumour using the immune system of the host, making it both selective and specific. In addition, the pipeline for HCC is evolving towards combination therapies with promising clinical outcomes. More drugs designed to focus on specific pathways and immune checkpoints are being developed in the clinic. It has been demonstrated that some drugs can improve the prognosis of patients with HCC in first- or second-line settings, and these drugs have been approved by the Food and Drug Administration or are nearing approval. This review describes targeting pathways and systemic treatment strategies in HCC and summarizes effective targeted and immune-based drugs for patients with HCC and the problems encountered. |
| first_indexed | 2024-12-17T00:23:55Z |
| format | Article |
| id | doaj.art-7d312a23b3354016841f266c29fb1510 |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-12-17T00:23:55Z |
| publishDate | 2021-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-7d312a23b3354016841f266c29fb15102022-12-21T22:10:30ZengBMCBiomarker Research2050-77712021-08-019111610.1186/s40364-021-00319-3Emerging treatment modalities for systemic therapy in hepatocellular carcinomaXin Qing0Wenjing Xu1Jingjing Zong2Xuanlong Du3Hao Peng4Yewei Zhang5Department of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast UniversityAbstract Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced HCC remains to be resolved. Fortunately, the past few years have shown the emergence of successful systemic therapies to treat HCC. At the molecular level, HCC is a heterogeneous disease, and current research on the molecular characteristics of HCC has revealed numerous therapeutic targets. Targeted agents based on signalling molecules have been successfully supported in clinical trials, and molecular targeted therapy has already become a milestone for disease management in patients with HCC. Immunotherapy, a viable approach for the treatment of HCC, recognizes the antigens expressed by the tumour and treats the tumour using the immune system of the host, making it both selective and specific. In addition, the pipeline for HCC is evolving towards combination therapies with promising clinical outcomes. More drugs designed to focus on specific pathways and immune checkpoints are being developed in the clinic. It has been demonstrated that some drugs can improve the prognosis of patients with HCC in first- or second-line settings, and these drugs have been approved by the Food and Drug Administration or are nearing approval. This review describes targeting pathways and systemic treatment strategies in HCC and summarizes effective targeted and immune-based drugs for patients with HCC and the problems encountered.https://doi.org/10.1186/s40364-021-00319-3Hepatocellular carcinomaTargeted therapyImmunotherapyTyrosine kinase inhibitorsImmune checkpoint inhibitorsSignalling pathway |
| spellingShingle | Xin Qing Wenjing Xu Jingjing Zong Xuanlong Du Hao Peng Yewei Zhang Emerging treatment modalities for systemic therapy in hepatocellular carcinoma Biomarker Research Hepatocellular carcinoma Targeted therapy Immunotherapy Tyrosine kinase inhibitors Immune checkpoint inhibitors Signalling pathway |
| title | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| title_full | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| title_fullStr | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| title_full_unstemmed | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| title_short | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| title_sort | emerging treatment modalities for systemic therapy in hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Targeted therapy Immunotherapy Tyrosine kinase inhibitors Immune checkpoint inhibitors Signalling pathway |
| url | https://doi.org/10.1186/s40364-021-00319-3 |
| work_keys_str_mv | AT xinqing emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma AT wenjingxu emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma AT jingjingzong emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma AT xuanlongdu emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma AT haopeng emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma AT yeweizhang emergingtreatmentmodalitiesforsystemictherapyinhepatocellularcarcinoma |